CIK 0000025743 · Non-accelerated filer<br>Smaller reporting company
TherapeuticsMD, Inc.
Sign in to watch- Ticker
- TXMD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- operating
- EIN
- 870233535
- Phone
- 561-961-1900
- Business address
- 951 YAMATO ROAD, SUITE 220, BOCA RATON, FL, 33431
- Former names
- AMHN, Inc., CROFF ENTERPRISES INC, CROFF OIL CO
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-11-30 | Donegan Michael C CAO and VP of Finance | Option exercise · Restricted Stock Units | −115,000 | 115,000 | ||
| 2021-11-18 | Collins Cooper C. Director | Purchase | +1,000,000 | $0.58 | $579K | 2,236,864 |
| 2021-10-15 | Glickman Mark A Chief Business Officer | Grant or award · Performance Stock Units | +260,000 | 260,000 | ||
| 2021-10-15 | Glickman Mark A Chief Business Officer | Grant or award · Restricted Stock Units | +260,000 | 260,000 | ||
| 2021-10-15 | Glickman Mark A Chief Business Officer | Grant or award · Restricted Stock Units | +400,000 | 400,000 | ||
| 2021-09-29 | Donegan Michael C CAO and VP of Finance | Grant or award · Restricted Stock Units | +38,954 | 38,954 | ||
| 2021-09-29 | Donegan Michael C CAO and VP of Finance | Other disposition · Non-Qualified Stock Option (right to buy) | −50,000 | 0 | ||
| 2021-09-29 | Donegan Michael C CAO and VP of Finance | Other disposition · Non-Qualified Stock Option (right to buy) | −100,000 | 0 | ||
| 2021-09-29 | Donegan Michael C CAO and VP of Finance | Other disposition · Non-Qualified Stock Option (right to buy) | −40,000 | 0 | ||
| 2021-09-29 | Donegan Michael C CAO and VP of Finance | Other disposition · Non-Qualified Stock Option (right to buy) | −100,000 | 0 | ||
| 2021-09-29 | Walker Marlan D General Counsel | Grant or award · Restricted Stock Units | +57,797 | 57,797 | ||
| 2021-09-29 | Walker Marlan D General Counsel | Other disposition · Non-Qualified Stock Option (right to buy) | −100,000 | 0 | ||
| 2021-09-29 | Walker Marlan D General Counsel | Other disposition · Non-Qualified Stock Option (right to buy) | −150,000 | 0 | ||
| 2021-09-29 | Walker Marlan D General Counsel | Other disposition · Non-Qualified Stock Option (right to buy) | −25,000 | 0 | ||
| 2021-09-29 | Walker Marlan D General Counsel | Other disposition · Non-Qualified Stock Option (right to buy) | −120,000 | 0 | ||
| 2021-08-31 | O'Dowd Hugh President | Grant or award · Performance Stock Units | +2,750,000 | 2,750,000 | ||
| 2021-08-31 | O'Dowd Hugh President | Grant or award · Restricted Stock Units | +2,750,000 | 2,750,000 | ||
| 2021-08-18 | Collins Cooper C. Director | Purchase | +900,000 | $0.72 | $648K | 1,236,864 |
| 2021-08-17 | Ling Karen Director | Purchase | +33,445 | $0.75 | $25K | 130,309 |
| 2021-08-17 | Collins Cooper C. Director | Purchase | +100,000 | $0.77 | $77K | 336,864 |
Page 8 of 11 · 206 trades